CDK2 and cholangiocarcinoma: Notably, we did not test whether dinaciclib affects its target genes, as Saqub et al. have already demonstrated the suppressed expression of Cdk2, Cdk5 and Cdk9 in CCA cell lines following dinaciclib treatment.4